XBiotech Inc. (NASDAQ:XBIT)’s share price traded up 3.8% on Tuesday . The stock traded as high as $15.75 and last traded at $15.70, with a volume of 51,479 shares traded. The stock had previously closed at $15.13.

Several equities analysts have recently weighed in on the stock. Zacks Investment Research downgraded shares of XBiotech from a “hold” rating to a “sell” rating in a research note on Saturday. Noble Financial reiterated a “buy” rating and issued a $30.00 target price (up previously from $24.00) on shares of XBiotech in a research note on Tuesday, June 28th.

The firm’s market capitalization is $506.10 million. The firm has a 50-day moving average of $15.27 and a 200-day moving average of $13.10.

In other news, Director W Thorpe Mckenzie purchased 20,000 shares of the company’s stock in a transaction that occurred on Thursday, May 26th. The shares were bought at an average price of $13.96 per share, for a total transaction of $279,200.00. Following the purchase, the director now directly owns 3,898,600 shares in the company, valued at approximately $54,424,456. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

XBiotech Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of diseases. The Company focuses on bringing its lead product candidate, Xilonix (MABp1), to market. The Company has also developed a True Human monoclonal antibody discovery platform and manufacturing system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.